GENEVA, June 24 -- AFFIMED GMBH filed a patent application (EP2025/084790) for “BISPECIFIC ANTIBODY CONSTRUCT DOSAGE REGIMEN FOR TREATING NSCLC”. With publication no. WO/2026/115158, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: A61K 39/395
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....